Recent blog posts
Progress in the Research and Development of GIPR Drug Targets
Progress in the Research and Development of GIPR Drug Targets
16 August 2023
Glucose-dependent insulinotropic polypeptide (GIP) is one of two enteroinsular hormones, playing a crucial role in linking nutrient intake with whole-body metabolism.
Read →
Progress in the Research and Development of JAK3 Drug Targets
Progress in the Research and Development of JAK3 Drug Targets
15 August 2023
JAK3 is a narrow-spectrum member that only regulates γc cytokines, thus becoming an ideal potential target.
Read →
How do AMPK activators target the intestines?
How do AMPK activators target the intestines?
14 August 2023
AMPK, which stands for AMP-activated protein kinase, is a key molecule in regulating energy metabolism and is at the core of research into diabetes and other metabolic-related diseases.
Read →
Progress in the Research and Development of cGAS-STING Drug Targets
Progress in the Research and Development of cGAS-STING Drug Targets
14 August 2023
The cGAS-STING signaling pathway is a cytoplasmic DNA sensing pathway that plays a critical role in innate immune responses.
Read →
Roche Clinical Trial Phase I of Oral Cyclic Peptide KRAS G12D Inhibitor
Roche Clinical Trial Phase I of Oral Cyclic Peptide KRAS G12D Inhibitor
10 August 2023
The KRAS G12D mutation affects approximately 180,000 patients in the United States and Europe, showing an incidence rate about 2.5 times higher compared to the KRAS G12C mutation.
Read →
The Discovery Process of a Novel STAT6 Inhibitor
The Discovery Process of a Novel STAT6 Inhibitor
9 August 2023
STAT6 is essential for IL-4 and IL-13 signal transduction, but it is downstream of the JAK/STAT pathway and is not utilized by other cytokines and growth factors.
Read →
What is the Prospect of Lilly's BTK Inhibitor LOXO305?
Valuable Targets
10 min read
What is the Prospect of Lilly's BTK Inhibitor LOXO305?
8 August 2023
While paying attention to the third-generation non-covalent BTK inhibitors, we can also consider other approaches to solve drug resistance.
Read →
Can JAK3 Replicate TYK2's Success?
Can JAK3 Replicate TYK2's Success?
8 August 2023
Among the JAK Family Members, JAK3, which Only Regulates a Narrow Spectrum of γc Cytokines, Emerges as a Potential Ideal Target.
Read →
CSF-1R inhibitor——the new layout of macrophage-targeted anticancer drugs
CSF-1R inhibitor——the new layout of macrophage-targeted anticancer drugs
8 August 2023
Tumor-associated macrophages (TAMs) can inhibit tumor immune efficacy. Colony stimulating factor 1 receptor (CSF-1R)/CSF-1 pathway involved in regulating the function of TAMs. CSF-1R is a tyrosine kinase transmembrane receptor, also a member of the growth factor CSF-1/platelet derived growth factor (PDGF) receptor family.
Read →
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
Valuable Targets
10 min read
The novel class of USP1 inhibitors opens up new frontiers for the treatment of cancers and diabetes
17 July 2023
the discovery and development of USP1 inhibitors certainly open up new frontiers for the treatment of a variety of diseases, including cancer, diabetes, and potentially even more.
Read →
Cdc42 provides a new target for treating Alzheimer’s Disease
Cdc42 provides a new target for treating Alzheimer’s Disease
13 July 2023
the small G protein family member, Cdc42, plays an important role in the progression of Alzheimer's disease.
Read →
Overview of the Development Progress of TIGIT Drug Target
Overview of the Development Progress of TIGIT Drug Target
11 July 2023
TIGIT, a major immune checkpoint molecule, is expressed on the surface of T cells and natural killer (NK) cells.
Read →